Thrombosis News and Research

Latest Thrombosis News and Research

Merits and risks of postmenopausal hormone therapy

The study was categorized as a primary prevention trial for coronary heart disease, although the fact that mean age at recruitment was 63 years was not given enough importance at that time. WHI investigators concluded that hormone therapy (HT) was not cardioprotective, and, in fact, its riskbenefit ratio did not favor the use of postmenopausal hormones for prevention of chronic diseases.

17 May 2007

High-dose clopidogrel before stenting cuts heart attack risk in half

Pretreatment with double-dose anticlotting medication just before percutaneous coronary intervention (PCI) cuts the combined risk of heart attack and cardiac death by half, according to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12, 2007, in Orlando, FL.

15 May 2007

Role of PCI and coronary artery bypass grafting for the treatment of patients with left main coronary artery disease

Coronary artery bypass surgery has been the preferred treatment for patients with a blockage in the left main coronary artery, the conduit that supplies blood to about two-thirds of the heart.

15 May 2007

Stent thrombosis

Over the last year, it's been rare to utter the word "stent" without at least thinking "thrombosis," an uncommon but serious complication that's been on the minds of interventional cardiologists and patients alike.

11 May 2007

Recent developments for drug-eluting stents

Drug-eluting stents -- small metal tubes used to prop open clogged arteries -- have been garnering headlines.

10 May 2007

Off-label and untested use of drug-coated stents is common in U.S. practice

The off-label and untested use of drug-coated stents in the treatment of coronary artery blockage is common in U.S. practice, and ischemic complication rates are higher among patients receiving drug-coated stents for off-label indications, according to two studies in the May 9 issue of Journal of the American Medical Association.

9 May 2007

Contrast-enhanced ultrasound after liver transplant is highly accurate in showing vascular as well as biliary complications

The study consisted of 39 liver transplant recipients who underwent a CE-US exam after developing fluid in the abdomen and/or unclear liver function tests.

8 May 2007

Scientists delete enzyme in mice so they can eat any type of fat and not get heart disease

A new study in mice raises a tantalizing possibility, that humans may one day be able to eat any kind of fat they want without raising their risk of heart disease.

8 May 2007

Caution against over-aggressive use of erythropoiesis-stimulating agents for cancer-related anemia

Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.

1 May 2007

Researchers identify antioxidant mechanisms involved in protection against heart disease

Zvonimir Katusic, M.D., Ph.D., and Mayo colleagues have identified antioxidant mechanisms essential for regenerative function of endothelial progenitor cells (EPCs).

30 Apr 2007

Students who hit the bottle increase their risk of heart problems

According to a study in the U.S., college students who over indulge in alcohol are increasing their risk for future heart disease.

22 Apr 2007

Risk and outcome similar for bypass surgery, drug-eluting stents

Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.

20 Apr 2007

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.

20 Apr 2007

Childhood sarcoma increases risk of blood clots

Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have determined that children and young adults with a form of cancer called sarcoma are at increased risk of having a thromboembolic event (TE) in their veins.

20 Apr 2007

College-age students who drink heavily may increase their risk for future heart disease

In a small study, Minnesota researchers found that a group of college students who drank heavily had higher levels of C-reactive protein (CRP), a blood marker for inflammation that can increase the risk for heart disease.

20 Apr 2007

Micell Technologies presents data on novel drug-eluting stents

Micell Technologies has announced that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 in Chicago, Illinois.

19 Apr 2007

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

ThromboGenics NV has announced that it has completed a global license agreement with Millipore Corporation under which ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(x).

17 Apr 2007

Long-term safety of drug-eluting stents in off-label use

Research presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent - a dangerous complication - and adherence and responsiveness to anti-clotting medication.

3 Apr 2007

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

Adding estradiol to a polymer-free rapamycin-eluting stent is not associated with any measurable benefit

Patients admitted to the hospital with acute coronary syndromes (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention (PCI), during which a stent is inserted into an occluded or narrowed coronary artery to restore blood flow to and from the heart.

2 Apr 2007

Thrombosis News and Research

Latest Thrombosis News and Research

Merits and risks of postmenopausal hormone therapy

High-dose clopidogrel before stenting cuts heart attack risk in half

Role of PCI and coronary artery bypass grafting for the treatment of patients with left main coronary artery disease

Stent thrombosis

Recent developments for drug-eluting stents

Off-label and untested use of drug-coated stents is common in U.S. practice

Contrast-enhanced ultrasound after liver transplant is highly accurate in showing vascular as well as biliary complications

Scientists delete enzyme in mice so they can eat any type of fat and not get heart disease

Caution against over-aggressive use of erythropoiesis-stimulating agents for cancer-related anemia

Researchers identify antioxidant mechanisms involved in protection against heart disease

Students who hit the bottle increase their risk of heart problems

Risk and outcome similar for bypass surgery, drug-eluting stents

Schering-Plough plans phase III trials for novel selective antiplatelet therapy

Childhood sarcoma increases risk of blood clots

College-age students who drink heavily may increase their risk for future heart disease

Micell Technologies presents data on novel drug-eluting stents

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

Long-term safety of drug-eluting stents in off-label use

Advances in clinical cardiology

Adding estradiol to a polymer-free rapamycin-eluting stent is not associated with any measurable benefit

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Thrombosis News and Research

Latest Thrombosis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in